ShigETEC Vaccine Study in Bangladesh

PHASE1RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 26, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ShigETEC live, attenuated, oral vaccine

"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."

OTHER

Placebo

"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."

Trial Locations (1)

Unknown

RECRUITING

International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b), Dhaka

Sponsors
All Listed Sponsors
lead

Eveliqure Biotechnologies GmbH

INDUSTRY

NCT05987488 - ShigETEC Vaccine Study in Bangladesh | Biotech Hunter | Biotech Hunter